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ABSTRACT: Bluetongue is a non-contagious acute viral disease affecting ruminants. It is a disease of great
clinical importance for the physical deterioration and the long convalescence that it causes and, from the economic
point of view, for the colossal production losses and prevention and control expenses. It is highly feared in spite
of being innocuous for man and of only medium mortality. Bluetongue virus spreads from animal to animal by
biting insects of the genus Culicoides and this is the reason for the disease being more prevalent in the geographic
areas where climate conditions are favorable for the insect development. The disease was described in detail in
early 1900, and at present, is one of the main concerns in animal health, being studied in order to clarify its
epidemiology and pathogenesis and to control its spreading. In this review, an attempt has been made to summarize
some aspects of the disease related to its history, economic importance and etiological agent, the viral genome
organization, the disease epidemiology and distribution, its clinical signs and lesions, as well as its diagnosis.
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Virus de la Lengua azul: un virus conocido, una amenaza presente
RESUMEN: La Lengua azul es una enfermedad viral no contagiosa, aguda, que afecta a los rumiantes. Es
una enfermedad de gran importancia clínica por el deterioro físico y la larga convalecencia que provoca y,
desde el punto de vista económico, por las colosales pérdidas de producción y gastos de prevención y control.
Es muy temida pese a ser inocua para el hombre y de solo mediana mortalidad. El virus se transmite entre los
animales por picaduras de insectos del género Culicoides, lo que hace que su prevalencia sea mayor en las
zonas geográficas donde el clima favorece el desarrollo de los mismos. Esta enfermedad se describió en detalle
a principios del siglo XIX y aún hoy constituye una de las principales preocupaciones en la salud animal, por lo
que se continúa estudiando para aclarar su epidemiología, patogenia y controlar así su diseminación. Esta revisión
tiene como objetivo resumir algunos aspectos de la enfermedad relacionados con su historia, importancia
económica, agente etiológico, organización del genoma viral, la epidemiología y la distribución, los signos clínicos
y lesiones, así como el diagnóstico de la enfermedad.
Palabras clave: Lengua azul, virus de la lengua azul, epidemiología, signos clínicos, diagnóstico.
INTRODUCTION
Bluetongue (BT) is an insect-transmitted viral
disease of ruminant species. It is listed as a ¨ notifiable
disease¨ by the Mundial Organisation for Animal Health.
This disease is caused by Bluetongue virus (BTV) (1).
BTV infection of ruminants is not contagious; the
virus is transmitted among hosts almost entirely by the
bites of certain species of Culicoides biting midges.
Thus, the distribution of BTV is restricted to areas
where competent vector species are present, and
transmission is limited to those times of the year when
climatic conditions are appropriate and adult insects
are active (2). Major signs are high fever, excessive
salivation, swelling of the face and tongue and cyanosis
of the tongue. Nasal symptoms may be prominent,
with nasal discharge and stertorous respiration. Some
animals also develop foot lesions (1). Laboratory
confirmation is based on virus isolation in embryonated
chicken eggs or mammalian and insect cell cultures.
For the identification of viruses to serogroup level,
immunofluorescence, antigen capture enzyme-linked
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immunosorbent assay or immunospot test are used.
Reverse-transcription polymerase chain reaction (RT-
PCR) and real time RT-PCR (rRT-PCR) have allowed
the rapid identification of BT viral nucleic acid. Serologic
techniques for the detection of BTV antibody include
complement fixation, agar gel immuno-diffusion and
competitive enzyme-linked immunosorbent assay,
indirect ELISA (1, 3).
HISTORY OF DISEASE
The bluetongue disease was already recognized
in South Africa in the early 19th century, where it was
initially called Malarial Catarrhal Fever or Epizootic
Catarrh of Sheep. The name of «bluetongue» was later
adopted to describe the distinctive cyanotic tongue of
some affected sheep. A comprehensive description of
the disease was not published until the first decade of
the 20th century (4, 5). In 1906, Arnold Theiler showed
that bluetongue was caused by a filterable agent (6).
For many decades bluetongue was thought to be
confined to Africa. It first achieved prominence outside
Africa during the 1950s and 1960s, when it caused
major outbreaks of the disease in Europe, killing over
179 000 sheep. Its identification at around the same
time in the Americas and Asia confirmed in the minds
of many farmers, scientists and legislators that it was
an emerging disease that could devastate the livestock
industries of the most advanced farming nations in
Europe, the Americas, and Australia. For these
reasons, it was allocated the status of a List ‘A’ disease
by OIE.
The first confirmed outbreak outside Africa
occurred in Cyprus in 1943 (7). Subsequent outbreaks
happened in this region, for example, in Israel (1949)
(8), Pakistan in 1959 (9) and in India in 1963 (10).
BTV was isolated and identified from Californian sheep
samples (11).
The first occurrence of BT in Europe, outside
Cyprus, was in 1956 when the disease was diagnosed
in southern Portugal (12) and shortly thereafter also in
Spain (13). The BTV infection was extended into the
Middle East and Asia and eventually into Australia and
Oceania (14, 15, 16).
During the 1970s and 1980s, in the absence of
major outbreaks of the disease, the perception that
BTV had reached its potential to emerge and should
be down-graded in importance and removed from the
OIE List ‘A’ category grew. More recently, possibly as
a result of climate change or other environmental
changes, BT has once again captured the attention of
much of the developed world, with extensions of new
serotypes into North America, Australia and Europe.
ECONOMIC IMPORTANCE
The economic losses due to BT are not expressed
in exact numbers, but the estimate is of three thousand
million dollars per year in the United States of America.
The losses are direct (death, abortion, loss of weight,
decreased milk production and efficiency of meat
production) and mainly indirect as a consequence of
the restrictions to the export of live animals, semen
and some products like bovine fetal serum. The costs
of the preventive measures and control should also be
taken into account. In the cases of higher disease
prevalence, the control measures may have a serious
impact on the amount of meat and animal products
available for the consumption market (17).
ETIOLOGY
Bluetongue is caused by the pathogenic virus of
the genus Orbivirus, Reoviridae family, species
bluetongue virus (18). Twenty-six serotypes are now
recognized for this virus (19). The virus particle
consists of ten strands of double-stranded RNA
surrounded by two protein shells. Unlike other
arboviruses, BTV lacks a lipid envelope. The particle
has a diameter of 86 nm (18).
VIRAL ORGANIZATION OF GENOMA
VIRAL PROTEINS
Seven of the viral proteins (VP1-VP7) are structural
and form the double-shelled virus particle. At least four
non-structural proteins (NS1, NS2, NS3, NS3A and
NS4) have been identified. The internal core is formed
by two layers containing VP1, VP3, VP4, VP6 and
VP7 [encoded by genome segment (Seg)-1, Seg-3,
Seg-4, Seg-9 and Seg-7, respectively]. These core
proteins and three of the non-structural proteins (NS1,
NS2 and NS4, encoded by Seg-5, Seg-8 and Seg-9,
respectively) are thought to be relatively conserved
and are antigenically cross-reactive between different
strains and serotypes of BTV (20).
Among the most studied proteins of the virus are
VP2, VP5, and VP7. VP2 and VP5 are two major viral
proteins that compose the outer capsid encoded by
Seg-2 and Seg-6, respectively, which determine the
antigenic variability of BTV (21). Seg-2 and Seg-6
show the highest levels of sequence variation in the
BTV genome (3); VP2 correlates perfectly with virus
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serotype, whereas VP5 shows partial correlation with
virus serotype. However, these segments vary within
each serotype and correlate with the geographical
origin of the virus strain (Seg-2 and Seg-6 topotypes).
NS3/NS3A proteins, encoded by Seg-10, have been
associated with the release of virus particles from insect
cells (22). The internal core protein VP7 can mediate
surface attachment, penetration and infection of insect
cells (3). Seg-7, encoding VP7, also shows significant
variations (23), despite the role of VP7 as the main
serogroup-specific antigen. It has been suggested that
this variation could also be related to the insect
populations that act as vectors for different virus strains
in different geographical areas (23).
EPIDEMIOLOGY AND DISTRIBUTION
Bluetongue occurrence is seasonal in the affected
Mediterranean countries, subsiding when temperatures
drop and hard frosts kill the adult midge vectors (24)
which may promote viral survival and vector longevity
during milder winters. A significant contribution to the
northward spread of Bluetongue disease has been the
ability of Culicoides obsoletus and C. pulicaris to
acquire and transmit the disease, both of which are
spread widely throughout Europe. This is in contrast
to the original C.imicola vector which is limited to North
Africa and the Mediterranean. The relatively recent
novel vector has facilitated a far more rapid spread
than the simple expansion of habitats north through
global warming.
During the period from late 2006 to 2007, BTV
appears to have fulfilled or exceeded all of the concerns
previously raised about its northerly extension in range
due to climate change and the involvement of Palearctic
vector species of Culicoides in the most northerly areas.
During 2006 a series of incursions of BTV into various
parts of the European region occurred; the most
significant incursion by far was the introduction of BTV-
8, a serotype new to Europe, into locations far beyond
the usual range of any BTV and indeed further north
than BTV had ever been recorded anywhere in the
world (e.g., up to 53°N). This outbreak was first
detected in the Maastricht area of the Netherlands in
August 2006. Cases of bluetongue were found not only
in the Netherlands, also in Belgium, Germany, and
Luxembourg. In 2007, the first case of bluetongue in
the Czech Republic was detected in one bull near Cheb
at the Czech-German border. In September 2007, the
UK reported its first ever suspected case of the disease,
in a Highland cow on a rare breed farm near Ipswich,
Suffolk. Since then the virus has spread from cattle to
sheep in Britain. By October 2007, bluetongue had
become a serious threat in Scandinavia and Switzerland,
and the first outbreak in Denmark was reported. In
autumn 2008, several cases were reported in the
southern Swedish provinces of Småland, Halland, and
Skåne, as well as in areas of the Netherlands bordering
Germany, which prompted veterinary authorities in
Germany to intensify controls. Norway saw its first
finding in February 2009, when cows at two farms in
Vest-Agder in the south of Norway showed an immune
response to bluetongue. Norway was declared free of
the disease in 2011 (25).
There are substantial data about the presence of
BTV in North America, Central America and the
Caribbean. Serotypes 1, 2, 3, 5, 6, 10, 11, 13, 14, 17,
19, 22, and 24 have been detected in North America,
whereas serotypes 1, 3, 4, 6, 8, 12, and 17 have been
identified in Central America and the Caribbean.
However, in South America, information regarding
detection of BTV is limited to very few reports.
Serological evidence for the presence of BTV has been
reported in Peru (26), Argentina (27), Brazil (28),
Ecuador (29), and Chile (30). The serotypes found by
serological techniques to be probably present in South
America are: 4, 6, 14, 17, 19, and 20 in Brazil (31);
12, 14, and 17 in Colombia (32); 14 and 17 in Guyana;
and 6, 14, and 17 in Suriname (33). Brazil and
Argentina are the only countries in South America
where BTV has been isolated. Clavijo et al. (34)
reported the first isolation of BTV in Brazil, and typed
it as serotype 12 by the seroneutralization test (SNT).
In Argentina the serotype 4 was determined by SNT
and RT-PCR (35).
The disease is not a threat to humans. It affects
domestic and wild ruminants and, although severe
forms of the disease are most frequent in sheep and
white-tailed deer, clinical signs can also occur in cattle,
goats and camelids (36). Although infection is often
unapparent in these other species, they can act as
reservoirs, remaining viraemic for several months
(particularly in cattle).
CLINICAL SIGNS AND LESIONS
Bluetongue occurs principally in sheep and some
species of wild ruminants. BTV infection of cattle, goats
and most wild ruminant species is typically
asymptomatic or subclinical (37).
The clinical signs of BTV infection are also highly
variable even in susceptible species such as sheep,
reflecting inherent differences in the susceptibility of
different sheep breeds, as well as of individual animals
and external stressors such as solar irradiation that
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can exacerbate the clinical signs of BT. The signs of
BT in sheep are the result of virus-mediated vascular
injury that produces oedema, hyperaemia and vascular
congestion, haemorrhage and tissue infarction (38).
Thus, sheep with acute BT have any combination of
fever, anorexia and malaise, respiratory distress,
excessive salivation, serous to bloody nasal and ocular
discharge that becomes increasingly mucopurulent so
that crusty exudates accumulate around the nostrils,
petechial and ecchymotic haemorrhages in the
mucous membranes of the oral and nasal cavities,
oral erosions and ulcers, lameness and/or a stiff gait,
hyperaemia and haemorrhage of the coronary band,
oedema of the head and neck (including the ears)
and congestion and focal haemorrhages in the
conjunctiva and skin. The swollen and cyanotic tongue
that gives the disease its name is uncommon. Mortality
rates vary from 0% in mild outbreaks to 30% or even
higher in outbreaks caused by virulent strains of BTV
in highly susceptible breeds of sheep. Most animals
that succumb to acute BT die within 14 days of infection
Sheep that survive the acute disease can have a
prolonged convalescence and some of them will show
substantial deterioration in body condition and become
emaciated. BTV induced muscle injury and necrosis
prevent normal locomotion in some animals and can
lead to torticollis (wryneck). The wool of convalescent
sheep is frequently shed (wool break), and some sheep
shed their hooves. These chronically affected sheep
may succumb to other diseases such as bacterial
pneumonia.
The post-mortem lesions of severe acute BT in
sheep include vascular congestion, haemorrhage,
erosion and ulceration of the mucosa of the upper
gastrointestinal tract (oral cavity, oesophagus,
forestomachs) and nasal cavity; sub-intimal
haemorrhages in the pulmonary artery; pulmonary
oedema with abundant froth in the trachea; pleural
and/or pericardial effusion; oedema within the fascial
planes of the muscles of the abdominal wall and
necrosis of skeletal and cardiac muscle with the
papillary muscle of the left ventricle being an especially
characteristic site (38).
Not all animals develop symptoms, but all those that
do lose condition rapidly, and the sickest animals die
within a week. For affected animals which do not die,
recovery is very slow lasting several months.
The incubation period is 5-20 days, and all symptoms
usually develop within a month. The mortality rate is
normally low, but it is high in susceptible breeds of
sheep. In Africa, local breeds of sheep may have no
mortality, but in imported breeds it may be up to 90
percent. Despite high virus levels in blood, infection is
usually asymptomatic in cattle, goats, and wild
ruminants. Red deer are an exception, and in them
the disease may be as acute as in sheep (39).
DIAGNOSIS
Diagnosis of BT is the identification of animals that
are or have previously been infected with the BTV.
CLINICAL DIAGNOSIS
Clinical signs as an early indicator of BTV infection.
Recognition of the clinical signs of BT can provide an
early indication of infection and forms a basis for
«passive surveillance», particularly in areas where BTV
is exotic and not the subject of routine «active
surveillance». Clinical diagnosis can therefore be of
critical importance, as BTV like many other exotic
diseases can spread rapidly and may quickly become
established within a naive and susceptible host
population. Early diagnosis leading to a rapid
implementation of control measures is therefore vital.
The infection may be widespread before the first clinical
signs are detected. The incursion of BTV-8 in northern
Europe was first detected in the Netherlands although
retrospective investigations indicate that the disease
had been present in the region for several weeks, with
many animals already infected in the Netherlands,
Belgium and Germany (40).
None of the typical clinical signs of BT in sheep
and cattle are pathognomonic. Any disease that causes
haemorrhage or oedema could be confused with BT,
such as foot-and-mouth (cattle, sheep and goats,
camelids, pigs), vesicular stomatitis (horses, pigs,
cattle, sheep and goats) malignant catarrhal fever
(cattle), mucosal disease and/or bovine viral diarrhoea
(cattle), orf (sheep), sheep and goat pox (sheep and
goats), peste des petite ruminants (sheep and goats),
rinderpest (cattle), lumpy skin disease (cattle),
infectious bovine rhinotrachaeitis (cattle), bovine
popular stomatitis/pseudo-cowpox (cattle), bovine
herpes mammillitis (cattle), contagious ovine digital
dermatitis (sheep), foot rot (sheep), clostridial
enterotoxaemia (sheep), non-infectious diseases:
photosensitisation (cattle and sheep), cobalt
deficiency (sheep), poising (e.g., bracken) (cattle and
sheep) (41).
The severity and range of clinical signs caused by
BTV in its hosts can also vary significantly and may
be influenced by a number of factors such as:
• The species breed and even individual animal
variations within a host species. BTV infection,
particularly in cattle, is frequently asymptomatic.
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• Age of the animal. There is some indication that
older animals may be more severely affected.
• Differences among infecting virus strains can
influence the severity of the clinical signs elicited,
ranging from inapparent to fatal.
• The immune status of the host. Antibodies
generated by previous infections with the same, or
even different strain/serotypes of the virus, or maternal
antibodies (colostrum), may have particular significance
in determining the outcome of the infection.
• Environmental stress (e.g., high levels of solar
radiation) can significantly influence the severity and
outcome of the disease caused by BTV infection.
The clinical diagnosis of BT always requires
confirmation by laboratory testing. Diagnostic samples
must be sent to a laboratory where BTV can be detected
and identified by appropriate diagnostic assay systems.
LABORATORY DIAGNOSIS
A positive diagnosis usually involves detection and
identification of BTV-specific antigens, antibodies or
RNA in diagnostic samples taken from animals
potentially infected using virus isolation and serological
or molecular assays to identify the virus serogroup
and serotype.
The BT «serogroup» reflects the presence of
antigens or RNAs that are both conserved and cross-
reactive between the different members of the virus
species this includes most of the BTV non-structural
and structural proteins of the virus core (particularly
VP7). Consequently, serogroup-specific assays can
detect any BTV strain and can be used to distinguish
it from the other orbiviruses.
BTV serotype is determined by the BTV outer
capsid proteins VP2 and VP5, particularly VP2, which
primarily controls the specificity of interactions with
neutralising antibodies in serum neutralisation assays.
In recent years, multiple strains of different BTV
serotypes have been introduced into Europe and other
areas, either by natural incursion or by the use of live
attenuated vaccines. It is particularly important to know
which serotype and strain of BTV is circulating in a
region to ensure the use of an appropriate vaccine.
These different BTVs can now also be detected and
differentiated by RT-PCR and phylogenetic analyses
targeting segment 2 (Seg-2) of the virus genome, which
codes for outer capsid protein VP2 (42; 3). However,
BTV also includes a number of distinct geographical
variants (topotypes) and subtypes, which show
distinctive nucleotide sequence variations in each of
their genome segments (including segment 2) (42).
Any of these serotypes, topotypes, and subtypes has
the potential to cause disease.
The identification of any individual «type» of BTV
can be used to demonstrate conclusively that the virus
belongs to the BTV serogroup/species and can
therefore be used to confirm an initial diagnosis.
Indeed, the identification of a specific BTV serotype
is cited as one of the most reliable methods of BTV
diagnosis (43).
Many of the different assays developed to identify
BTV, or animals that have been infected with the virus,
are commonly referred to as «group-specific». BTV
group-specific assays include serological methods to
detect BTV-specific antibodies generated during
infection of the mammalian host, serological assays to
detect and identify BTV-specific protein antigens, and
molecular techniques such as RT-PCR and cDNA
sequencing/phylogenetic analyses that can be used
to detect and identify BTV RNA extracted from
diagnostic samples (e.g., blood, spleen, and insects).
These assays may also involve or depend on the
isolation of the virus and its growth in cell culture.
DIAGNOSTIC TECHNIQUES
1- Identification of the BTV agent
a) Virus isolation. The same diagnostic procedures
are used for domestic and wild ruminants. A number
of virus isolation systems for BTV are in common use,
but the most sensitive method is by inoculation of
embryonated chicken eggs (ECE). Inoculation of sheep
may also be a useful approach if the viral titer in the
blood sample is very low, as may be the case several
weeks after virus infection. Attempts to isolate virus in
cultured cells in vitro may be more convenient, but the
success rate is frequently much lower than that
achieved with in vivo systems (44).
b) Immunological methods
• Serogrouping of viruses. Orbivirus isolates are
typically serogrouped on the basis of their reactivity
with specific standard antisera that detect proteins,
such as VP7, that are conserved within each
serogroup. A BT serogroup-specific MAb can be used.
A number of laboratories have generated such
serogroup-specific reagents. Commonly used methods
for the identification of viruses to serogroup level are:
immunofluorescence, antigen capture enzyme-linked
immunosorbent assay, immunospot test (45).
• Serotyping by virus neutralization
Neutralization tests are type specific for the currently
recognized 26 BTV serotypes and can be used to
serotype a virus isolate or can be modified to determine
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the specificity of antibody in sera. In the case of an
untyped isolate, the characteristic regional localization
of BTV serotypes can generally obviate the need to
attempt neutralization by all 26 antisera, particularly
when endemic serotypes have been identified.
c) RT-PCR, sequence analyses and phylogenetic
comparisons, molecular probes and electrophoresis.
-RT-PCR techniques have allowed the rapid
identification of BT viral nucleic acid in blood and other
tissues of infected animals. The RT-PCR procedure
will detect virus-specific nucleic acid, but this does
not necessarily indicate the presence of infectious
virus. RT-PCR can also be used to ‘serogroup’
Orbiviruses and may ultimately be possible to ‘serotype’
BTV within a few days of receipt of a clinical sample,
such as infected sheep blood (3).
-rRT-PCR tests there are two published real-time
assays that have been shown to detect all 26 serotypes
(46). A further development is of triplex and duplex
assay kits that detect a combination of groups, BTV-8,
BTV-1, BTV-6, and internal control.
2- Serological tests
Complement fixation, agar gel immunodiffusion
competitive enzyme-linked immunosorbent, indirect
ELISA (1).
Anti-BTV antibodies generated in infected animals
can be detected in a variety of ways that vary in
sensitivity and specificity. Both serogroup-specific and
serotype-specific antibodies are elicited and if the
animal was not previously exposed to BTV, the
neutralizing antibodies generated are specific for the
serotype of the infecting virus. Multiple infections with
different BTV serotypes lead to the production of
antibodies capable of neutralizing serotypes to which
the animal has not been exposed.
CONCLUSIONS
Despite the significant advances and developments
achieved in BTV diagnosis, further efforts in this regard
continue being required due to the expansion of this
virus into new areas and the need for better and faster
assays.  The advent of real-time RT-PCR assays has
already increased sensitivity and the speed with which
BTV can be detected and identified, and these
technologies are currently being applied to the typing
of BTV in diagnostic samples. However, it is important
to keep in mind that the segmented nature of the BTV
genome and the ability of different virus strains to
reassort their genome segments make genome segment
2 (and possibly segment 6) the only valid targets for
serotyping assays. Variations in the other genome
segments do not reliably correlate with virus serotype
(47). Real-time RT-PCR assays to detect and identify
BTV serotypes 1 and 8 are commercially available.
Assays for detecting a specific strain of BTV can be
rapidly designed and produced; however, the design
and validation of those assays that are reliable serotype-
specific take much longer and are more difficult to
undertake, but the development of such monoplex and
multiplex real-time assays that can be used to detect
and distinguish all 26 BTV serotypes is currently
underway.
Robust and reliable ‘pen-side’ assays for BTV based
either on antibody/antigen detection methods or on
RT-PCR could offer significant and possible vital time
savings in diagnosis. The further development of probe-
based diagnostic systems, using libraries of
oligonucleotides printed on chips, could enable
detection of BTV and other orbiviruses even to serotype
level. Printing of different peptide or protein antigens
into ELISA plates also has the potential to allow testing
of antibodies against a wide range of pathogens in a
single plate, or even a single well. However,
distinguishing between animals that have received live-
attenuated or semi-purified inactivated BTV vaccines
and naturally infected animals is likely to remain
problematic. The development of the next generation
of subunit vaccines will ease the problems of designing
and producing an effective DIVA assay.
The scientific community must continue working
for more sensible and robust diagnostic methods so
that this viral disease be controlled in a more effective
way to avoid or minimize the damages caused by it.
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